Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Invested Capital: 2019-2023

  • Lineage Cell Therapeutics' Return on Invested Capital was N/A to -0.11% in Q1 2023 from the same period last year, while for Mar 2023 it was -0.11%, marking a year-over-year change of. This contributed to the annual value of -0.33% for FY2023, which is N/A change from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Return on Invested Capital stood at -0.11% for Q1 2023, which was up 72.12% from -0.40% recorded in Q3 2022.
  • In the past 5 years, Lineage Cell Therapeutics' Return on Invested Capital ranged from a high of -0.02% in Q3 2021 and a low of -0.40% during Q3 2022.
  • Its 3-year average for Return on Invested Capital is -0.18%, with a median of -0.11% in 2023.
  • Data for Lineage Cell Therapeutics' Return on Invested Capital shows a maximum YoY plummeted of 37bps (in 2022) over the last 5 years.
  • Lineage Cell Therapeutics' Return on Invested Capital (Quarterly) stood at -0.21% in 2019, then reached -0.02% in 2021, then tumbled by 37bps to -0.40% in 2022, then reached -0.11% in 2023.
  • Its last three reported values are -0.11% in Q1 2023, -0.40% for Q3 2022, and -0.02% during Q3 2021.